Analyst Price Targets — TMO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 30, 2026 2:25 pm | — | UBS | $615.00 | $579.86 | TheFly | Thermo Fisher price target raised to $615 from $590 at UBS |
| January 30, 2026 2:08 pm | — | Wells Fargo | $683.00 | $580.09 | StreetInsider | Thermo Fisher Scientific (TMO) PT Lowered to $683 at TD Cowen |
| January 30, 2026 12:27 pm | — | Robert W. Baird | $653.00 | $583.12 | TheFly | Thermo Fisher price target raised to $653 from $645 at Baird |
| January 30, 2026 10:36 am | — | Barclays | $650.00 | $592.16 | TheFly | Thermo Fisher price target raised to $650 from $625 at Barclays |
| January 9, 2026 12:36 pm | Daniel Arias | Stifel Nicolaus | $700.00 | $606.50 | TheFly | Thermo Fisher price target raised to $700 from $583 at Stifel |
| January 5, 2026 2:55 pm | Vijay Kumar | Evercore ISI | $650.00 | $605.83 | TheFly | Thermo Fisher price target raised to $650 from $610 at Evercore ISI |
| December 15, 2025 11:30 am | — | Wells Fargo | $675.00 | $571.99 | TheFly | Thermo Fisher price target raised to $675 from $635 at Wells Fargo |
| December 9, 2025 9:27 am | Evie Koslosky | Goldman Sachs | $685.00 | $568.21 | TheFly | Thermo Fisher initiated with a Buy at Goldman Sachs |
| December 7, 2025 11:55 pm | Paul Knight | KeyBanc | $750.00 | $572.77 | TheFly | Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc |
| October 29, 2025 2:08 pm | — | Argus Research | $610.00 | $570.82 | TheFly | Thermo Fisher price target raised to $610 from $580 at Argus |
Latest News for TMO
Thermo Fisher Scientific is reiterated as a 'buy' with a fair value estimate of $619 per share, reflecting confidence in its recovery and strategic positioning. TMO's acquisition of Clario Holdings for $8.875 billion is expected to enhance recurring revenue, accelerate organic growth, and support future AI-driven clinical trial solutions. Management guides for 3%-4% organic revenue growth and 6%-8% adjusted EPS…
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1.…
The March 2026 Top 15 dividend growth stocks list targets high-quality, undervalued companies with a projected 21.28% long-term CAGR and 1.13% average yield. Pure Quality and Value-focused stock selection strategies outperformed the original blended approach in February, though all variants posted negative returns for the month. Since inception, the watch list has underperformed SPY and VIG, with an 8.82% annualized…
APG Asset Management N.V. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 37.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 848,734 shares of the medical research company's stock after buying an additional 229,028
Andra AP fonden cut its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 75.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,798 shares of the medical research company's stock after selling 20,600 shares during the period. Andra
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.